Use the hyperlinks, where available to access additional clinical trial information.
A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma
Other Non-Commercial Sponsor
Melanoma and Skin Cancer Trials Limited
Eligible patients will be randomised to receive 6 months of Avelumab at a dose of 800mg or a placebo as a 60-minute intravenous infusion once every 2 weeks (13 doses)